Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the latest advancements in the field, highlighting the use of opioids and the future for cannabinoids within the pain therapeutics field. Furthermore, policy experts will provide an essential regulatory perspective for this year's agenda, providing an exciting and comprehensive insight into the pain therapeutics market.
Register your place online at: www.pain-therapeutics.co.uk/PR4OpenPR
In recent news, AOBiome's B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema). AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus (itch) and appearance of atopic dermatitis (eczema).
The trial enrolled 547 patients with mild-to-moderate appearance of atopic dermatitis and moderate-to-severe itch. The trial met all primary and secondary endpoints, showing that B244 significantly reduced itch, reduced overall disease severity, improved skin clearance, and improved health-related quality of life measures at 4 weeks compared to placebo.
•B244 reduced patients' WI-NRS score by an average of 34.3% and achieved clinically meaningful 4-point itch response
•Lesional severity (appearance) improved for IGA and EASI
•Results were achieved in 4 weeks
•Safe and well tolerated with no SAEs and no single adverse event occurred in greater than 1% of the active group.
SMi Group are delighted to announce that Todd Krueger, President and CEO from AOBiome will be presenting on day 1 of the Pain Therapeutics Conference 2022 on AOBiome's Drug Development Program for the Treatment of Pruritus associated with Atopic Dermatitis which will cover:
•An introduction to Atopic Dermatitis and Pruritus
•Discussion of mechanisms and pre-clinical development work
•Review of clinical results and the challenges faced
•The future outlook for this research
SMi Group also caught up with Todd Krueger, President and CEO, AOBiome for an exclusive speaker interview to discuss his role, breakthroughs, challenges and upcoming projects.
To download your complimentary copy, please visit: www.pain-therapeutics.co.uk/PR4OpenPR
SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For details contact Andrew Gibbons on +44 (0)20 7827 6156 or email at email@example.com
SMi's 22nd Annual Pain Therapeutics Conference
4th - 5th May 2022
India House, 45 Curlew Street
--- ENDS -
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference here
News-ID: 2602460 • Views: 664
More Releases from SMi Group
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The
Assessing device development and regulation for advanced innovation
Pre Filled Syringes West Coast USA Conference 2022 Launches Assessing device development and regulation for advanced innovation SMi's 6th Annual Conference Pre-Filled Syringes West Coast June 13 - 14, 2022 | San Diego, CA, USA http://www.prefilled-syringes-westcoast.com/ SMi is delighted to announce the 6th annual Pre-Filled Syringes West Coast conference, to be held in San Diego. As part of SMi's leading series of drug delivery device conferences, the 2022 event will provide insights into the rapidly
More Releases for AOBiome
Korea Probiotic Cosmetic Products Market to See Huge Growth by 2028 | Unilever, …
Korea Probiotic Cosmetic Products Market - Global Trends, Insights to 2028 is latest research study released by HTF MI evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Korea Probiotic Cosmetic Products Market. Some of the key players profiled in the study are Estee
Human Microbiome Market advanced technology, future potential, forecast 2021-203 …
New York,According to a new market research report published by Global Insight Services Human Microbiome Market is expected to reach US$ XX bn by 2031. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market. The human microbiome
Probiotic Cosmetic Products Market to Witness Huge Growth by Key Players: Estee …
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Probiotic Cosmetic Products industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Probiotic Cosmetic Products market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Probiotic Cosmetic Products report includes a
Human Microbiome Market Global Research and Clinical Analysis 2021 to 2026 - AOB …
The “Global Human Microbiome Market” Research Report 2021-2026 is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from industry experts and professionals. The study is a detailed document on key aspects of the markets including trends, segmentation, growth prospects, opportunities, challenges, and competitive analysis. The global
Human Microbiome Market by Type by End User ViThera Pharmaceuticals, Second Geno …
Human microbiome play a major role in modern healthcare, as it allows easy digestion of food, regulation of immune system, and production of vitamins such as Vitamin K, Vitamin B, and Vitamin B12, which is essential for blood coagulation. The global human microbiome market size was valued at US$ 46,913.4 million in 2017, and is expected to exhibit a CAGR of 17.5% over the forecast period (2018 – 2026). Human microbiome boosts
Migraine -Pharmaceutical and Healthcare latest Analysis | Key Players Covered Am …
HTF Market Intelligence released a new research report of 231 pages on title 'Migraine - Pipeline Review, H2 2018' with detailed analysis, forecast and strategies. Request a sample report @ https://www.htfmarketreport.com/sample-report/1429046-migraine-pipeline-review-5 About Migraine :Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and